



Granules India Limited

Regd. Off. :

2nd Floor, 3rd Block, My Home Hub, Madhapur, Hyderabad - 500 081. INDIA

Ph : +91-40-30660000, 66760000 Fax : +91-40-23115145

E-mail : mail@granulesindia.com URL : www.granulesindia.com

CIN : L24110TG1991PLC012471

Dated June 09, 2016

To,
National Stock Exchange of India Limited
Bombay Stock Exchange Limited
Symbol: NSE: GRANULES; BSE: 532482

Sub: Granules Pharmaceuticals, Inc., wholly owned subsidiary of Granules India Limited, entered into an exclusive agreement with USpharma Windlas, LLC for product in-licensing - Press Release-Reg.

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir,

With reference to the captioned subject, please find herewith a copy of Press Release issued by the Company.

This is for your information and dissemination to the members of the exchange.

Thanking You.

Yours faithfully,

For GRANULES INDIA LIMITED

T. Chaitanya.

**CHAITANYA TUMMALA
(COMPANY SECRETARY &
COMPLIANCE OFFICER)**





Press Release

Granules Pharmaceuticals, Inc., wholly owned subsidiary of Granules India Ltd entered into an agreement for product in-licensing.

Hyderabad India, June 09 2016: Granules India Ltd., today announced that its wholly owned subsidiary Granules Pharmaceuticals, Inc., (GPI) has acquired the exclusive rights from USpharma Windlas, LLC to market and distribute four products in the USA.

USpharma Windlas through its subsidiaries (First time US Generics and Liberty) holds Abbreviated New Drug Applications (ANDAs) for Fingolimod, Prasugrel, Dronedarone and Lurasidone. USpharma Windlas believes to be a first applicant to file ANDAs containing paragraph IV certifications for three of these products.

USpharma Windlas will receive milestone payments and share of the profits from commercial sales. Granules Pharmaceuticals, Inc. will be responsible for the marketing and distribution of the products in the United States, subject to final approval by the U.S. Food and Drug Administration (US FDA).

According to IMS Health data, the annual U.S. sales for above four products are approximately \$4.4 billion.

“Product in-licensing is a strategic manoeuvre to accelerate our business expansion plans in the USA by fostering long term partnerships” said Mr. Krishna Prasad Chigurupati, Chairman and Managing Director, Granules India Ltd.

About Granules India Ltd. (BSE: 532482, NSE: GRANULES)

Granules is a fast growing pharmaceutical manufacturing company with world class facilities and is committed to manufacturing excellence, quality and customer service. The Company produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) for customers in the regulated and semi-regulated markets. Granules support customers with its product range, unique value, , proactive solutions. The Company’s global presence extends to over 300 customers in 60 countries through offices in India, U.S., U.K., China and Colombia. Granules India offers all three components of the pharmaceutical value chain which gives the customers flexibility and choice.



About USpharma Windlas, LLC.

USpharma Windlas, LLC is a joint venture between USpharma, Ltd and Windlas Healthcare Private Limited. USpharma is a development-stage pharmaceutical company specializing in the research, development and manufacturing of high-barrier generic pharmaceuticals, including controlled-release, controlled-substance and patent-challenge products. USpharma has filed these ANDA's and has a pipeline of several high-barrier products. Windlas Healthcare Private Limited is a complex generics focused pharmaceutical company that develops, manufactures and sells products in several regulated markets. Windlas has R&D center and manufacturing facility approved by FDA.

Caution Statement:

Certain statements made above may be "forward looking statements" within the meaning of applicable laws and regulations.

Contacts:

Sumanta Bajpayee

Granules India Ltd.

040-30663572

sumanta.bajpayee@granulesindia.com